Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
561-05-003 ISMRM Abstract

MR Cytometry for Ovarian Tumors: Differentiation of Benign and Malignant Lesions and Correlation with Pathology

Primary: Body - Urogenital
Secondary: Diffusion - Microstructure
561-05-003 · Advanced MR Techniques in Cervical, Genital, Placental, and Fetal Disorders · Wednesday, 13 May, 4:00 PM–4:55 PM · Digital Posters Row B
Keywords: Magnetic resonance imaging MR cytometry Microstructural parameters Pathological characteristics Ovarian Tumors
Accepted
Wenyi Yue 1, Dandan Zheng2, Junzhong Xu3, Chaoyang Jin3, Xiaoyu Jiang3, Qi Yang4
1Department of Radiology, Beijing Chaoyang Hospital, Capital Medical University, beijing, China
2Clinical & Technique Support, Philips Healthcare (Beijing), Beijing, China
3Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, United States of America
4Beijing Chaoyang Hospital, Capital Medical University, beijing, China
Presenting Author: Wenyi Yue

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. TüRKOĞLU S, KAYAN M. Differentiation between benign and malignant ovarian masses using multiparametric MRI [J]. Diagnostic and interventional imaging, 2020, 101(3): 147-55.doi: 10.1016/j.diii.2020.01.006 [doi]
2. CAO Y, LU Y, SHAO W, et al. Time-dependent diffusion MRI-based microstructural mapping for differentiating high-grade serous ovarian cancer from serous borderline ovarian tumor [J]. European journal of radiology, 2024, 178: 111622.doi: 10.1016/j.ejrad.2024.111622 [doi]
3. DESTELI G A, GULTEKIN M, USUBUTUN A, et al. Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature [J]. World journal of surgical oncology, 2010, 8: 106.
4. DUSKA L R, KOHN E C. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications [J]. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 28(suppl_8): viii8-viii12.doi: 10.1186/1477-7819-8-106 [doi]
5. DELL' ANNA T, SIGNORELLI M, BENEDETTI-PANICI P, et al. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial [J]. British journal of cancer, 2012, 107(5): 785-92.doi: 10.1038/bjc.2012.336 [doi]
6. JIANG X, DEVAN S P, XIE J, et al. Improving MR cell size imaging by inclusion of transcytolemmal water exchange [J]. NMR in biomedicine, 2022, 35(12): e4799.doi: 10.1002/nbm.4799 [doi]
7. LIU F, WU L, LUO X, et al. Evaluating the Diagnostic Performance of MR Cytometry Imaging in Differentiating Benign and Malignant Breast Tumors [J]. Journal of magnetic resonance imaging : JMRI, 2025, 62(2): 521-33.doi: 10.1002/jmri.29757 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/561-05-003